Capivasertib(Truqap) is a new type of targeted therapy for patients with specific types of advanced or metastatic breast lesions. The drug works by inhibiting the PI3K/AKT signaling pathway, providing a new treatment option for patients with hormone receptor (HR) positive, HER2 negative and PIK3CA/AKT1/PTEN gene mutations.
A brief introduction to Capivasertib
Capivasertib combined with fulvestrant is approved for the treatment of patients with HR positive, HER2 negative, locally advanced or metastatic breast lesions.
Indications and applicable populations
Applicable populations need to be confirmed by genetic testing for the presence of PIK3CA, AKT1 or PTEN gene mutations, and the disease progresses after at least one endocrine therapy, or relapses within 12 months after adjuvant therapy. The specifications of the generic drug produced by Lucius in Laos are 160mg*64 tablets and 200mg*64 tablets, which can be obtained through formal channels.
Dosage regimen and dose adjustment
The standard recommended dose is 400mg orally twice daily, taken for 4 consecutive days, and then stopped for 3 days until disease progression or intolerable toxicity occurs. The missed dose should be taken within 4 hours, and the dose should be skipped if it exceeds 4 hours. When used in combination with strong CYP3A inhibitors, the dose should be adjusted to 320mg twice daily, and the doctor's instructions should be strictly followed.
Understanding the basic medication principles of Capivasertib is the basis for ensuring the treatment effect. The following content will detail the matters that need special attention during use.
Precautions for Capivasertib
Capivasertib may cause serious adverse reactions, and patients need to closely monitor their physical condition and adjust the treatment plan according to the doctor's advice. The following are two key precautions.
Hyperglycemia and diabetes management
Capivasertib may cause severe hyperglycemia or even ketoacidosis. Fasting blood glucose (FG) and glycosylated hemoglobin (HbA1c) should be tested before treatment. FG should be monitored at least once a month during treatment, and HbA1c should be tested every three months. If symptoms such as thirst, polyuria, and weight loss occur, seek medical attention immediately. Patients with type 1 diabetes or those who rely on insulin therapy need to carefully assess the risks of medication.
Skin and digestive tract adverse reactions
About 20% of patients will experience skin reactions (such as erythema, rash) or severe diarrhea. It is recommended to carry antidiarrheal drugs with you and increase the amount of fluid replacement when diarrhea occurs. Skin symptoms require prompt consultation with a dermatologist, and if necessary, the dose should be adjusted or the drug should be discontinued. If erythema multiforme or DRESS syndrome occurs, treatment should be terminated immediately.
Strictly following the precautions can reduce the risk of treatment. The following content will explain the effect of diet on the efficacy of Capivasertib.
Dietary principles for Capivasertib
Reasonable eating habits can help improve the efficacy of the drug and reduce side effects. Patients need to adjust their daily diet according to treatment needs.
Avoid taking with specific foods
The absorption of Capivasertib may be affected by a high-fat diet. It is recommended to avoid consuming large amounts of oil within 1 hour before and after taking the drug. Grapefruit or grapefruit juice may interfere with drug metabolism and lead to abnormally high blood drug concentrations. Such foods should be completely avoided during treatment.
Nutritional support and blood sugar control
A high-protein, low-glycemic index (GI) diet helps stabilize blood sugar levels. It is recommended to choose whole grains, green leafy vegetables and lean meat, and reduce the intake of refined sugar and processed foods. If you experience loss of appetite or weight loss, you can eat small meals frequently and supplement with nutritionally fortified drinks.
Scientific dietary management can help improve the treatment effect. Patients need to communicate with their doctors regularly about their physical condition and adjust their medication and lifestyle in a timely manner. If you need to store the drug for a long time, please place Capivasertib in its original packaging and store it in a dry, dark environment at 15°C-30°C. Maintaining a positive attitude during treatment and cooperating with the medical team to develop a personalized plan are important supports for defeating the disease.
